ASX:BIT

Biotron (BIT) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.03 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
5.08%
Price Target
N/A
BIT stock logo

About Biotron Stock (ASX:BIT)

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.

BIT Stock News Headlines

BBC micro:bit playground survey
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
The Best Multi-Bit Screwdriver
BBC micro:bit - the next gen
Biotron Limited (BIT.AX)
Biotron Drug Effective Against COVID-19 In Animals
See More Headlines
Receive BIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotron and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-4,020,000.00
Net Margins
-244.54%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.65 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.60
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Michelle Miller BSc.
    GCertAppFin, MSc., Ph.D., MD & Executive Director
  • Mr. Peter James Nightingale B.Econ (Age 67)
    CA, Company Secretary
    Comp: $120k
  • Dr. Stephen L. Becker M.D.
    Chief Medical Officer

BIT Stock Analysis - Frequently Asked Questions

This page (ASX:BIT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners